Supplementary statement regarding the news article by Economy Daily News
Date of occurrence of the event: Dec 20,2019 Company name: OBI Pharma, Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: Not applicable …
OBI Pharma Announces Initiation of a Phase 1/2 Study of Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999.
TAIPEI, Taiwan, December 18, 2019 ─ OBI Pharma, a Taiwan biopharma company (TPEx: 4174), today announced the initiation of a Phase 1/2 clinical trial (ClinicalTrials.gov Identifier: NCT04084366) of OBI-999, an …
Board of Directors Agreed Subsidiary OBI Pharma (Shanghai) Limited to Implement Partial Intellectual Property Rights of Headquarter – Rights in China
Date of occurrence of the event: Nov 28, 2019 Company name: OBI Pharma, Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head Office Reciprocal shareholding ratios: Not …
Announcement on Change of General Manager
Date of the board of directors’ resolution or date of occurrence of the change: Nov 28, 2019 Type of personnel (chairman or general manager): General Manager Name and resume of …
Clarification on news articles
Date of occurrence of the event: Nov 26, 2019 Company name: OBI Pharma, Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: Not …
Explanation on news article by Economy Daily News
Date of occurrence of the event: Nov 25, 2019 Company name: OBI Pharma, Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: Not …
OBI Pharma Inc. to attend Investor Conference hosted by Masterlink Securities
1.Date of the event:Nov 25, 2019 2.Time: 14:30:00 NST 3.Location:Masterlink Securities (Address: No.97-11, Sec. 2, Dunhua S. Rd., Da’an Dist., Taipei City 106, Taiwan) 4.Summary: OBI Pharma Inc. to attend …
Announcement of phase II clinical trial result for ovarian cancer on OBI and Mackay Memorial Hospital cooperated Adagloxad Simolenin, OBI-822
Date of occurrence of the event: Sep 16, 2019 Company name: OBI Pharma, Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: Not …
Announcement on change of research and development officer
Type of personnel changed (please enter: spokesperson, acting spokesperson, important operational officer, financial officer, accounting officer, company secretary, research and development officer, or internal audit officer): Research and development officer …
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of its Antibody-Drug Conjugate (ADC) targeted cancer therapy, OBI-999
First Clinical Trial to test the Safety and Efficacy of based on an ADC (Antibody Drug Conjugate) targeting Globo H, a glycolipid antigen found on multiple tumor types. TAIPEI, Taiwan, …